Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.
Home 2025
Archives
Tracing evolution’s blueprint: Minimal genome life and the engineering of synthetic endosymbiosis
Roksana Riddle and Christopher H. Contag from Michigan State University discuss the concept of endosymbiosis, how it has evolved, and present strategies to engineering endosymbionts and their applications in developing innovative therapies.
Neuroengineering with engineered endosymbionts
Christopher H. Contag and Ahmed A. Zarea from Michigan State University’s Institute for Quantitative Health Science and Engineering explore therapeutic approaches to neurodegenerative diseases using a novel strategy based on engineered endosymbionts systems that could revolutionize patient care.
Engineering interkingdom communication for next-generation therapeutic approaches
Brian Snyder and Christopher H. Contag, from Michigan State University, discuss engineering interkingdom communication, which is not for palace intrigue, but for next-generation therapeutic approaches they argue.
Institute for Quantitative Health Science and Engineering (IQ)
Professor Christopher Contag is the founding director of the Institute for Quantitative Health Science and Engineering at Michigan State University; the Institute was founded in 2016 and is known as IQ.
What imaging reveals about engineered endosymbionts
Ashley V. Makela and Christopher H. Contag from the Institute for Quantitative Health Science and Engineering, walk us through watching living therapeutics in action, including what imaging reveals about engineered endosymbionts.
Engineered endosymbionts as novel cancer therapeutics
Satyajit Hari Kulkarni and Christopher H. Contag from the Institute for Quantitative Health Science and Engineering focus on engineered endosymbionts, which they argue is a paradigm shift in anticancer bacteriotherapy toward killing tumors from the inside out.
Engineered endosymbionts for cellular control
Christopher H. Contag from the Institute for Quantitative Health Science and Engineering (IQ) at Michigan State University discusses the potential of engineered endosymbionts as biologically encoded remote controls for regenerative medicine.
